Guided Therapeutics, Inc. Awarded Third Year Funding of National Cancer Institute Grant for LuViva(TM) Advanced Cervical Scan

Published: Aug 25, 2011

NORCROSS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTCBB & OTCQB: GTHP), developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced that it was awarded $517,000 to fund the third year of a $2.5 million three-year grant from the National Cancer Institute (NCI). The grant provides additional resources to help commercialize and bring to market the LuViva™ Advanced Cervical Scan and Cervical Guide single-patient-use disposable. LuViva is currently under pre-market approval (PMA) review by the U.S. Food and Drug Administration.

Back to news